NeuroSense Therapeutics (NRSN) Interest & Investment Income (2021 - 2023)
NeuroSense Therapeutics (NRSN) posted Interest & Investment Income of $338000.0 for Q4 2023, down 90.85% sequentially from $3.7 million in Q3 2023, and up 64.08% YoY from $206000.0 in Q4 2022.
NeuroSense Therapeutics (NRSN) Interest & Investment Income (2021 - 2023) Analysis & Trends
NeuroSense Therapeutics has reported Interest & Investment Income for 3 years, with the latest figure at $338000.0 in Q4 2023.
- Quarterly Interest & Investment Income rose 64.08% year-over-year to $338000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.2 million (up 236.6% YoY) and the FY2023 annual result came in at $4.2 million, up 236.6% from the prior year.
- Interest & Investment Income declined to $338000.0 in Q4 2023 per NRSN's latest filing, from $3.7 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $3.7 million in Q3 2023 and troughed at $62000.0 in Q1 2023.
- A 3-year average of $913000.0 and a median of $335000.0 in 2022 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income tumbled 92.45% in 2022, then surged 1002.39% in 2023.
- Over 3 years, Interest & Investment Income stood at $2.7 million in 2021, then sank by 92.45% to $206000.0 in 2022, then jumped by 64.08% to $338000.0 in 2023.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $338000.0, $3.7 million, and $138000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 338,000.00 |
| Sep 30, 2023 | 3.69 Mn |
| Jun 30, 2023 | 138,000.00 |
| Mar 31, 2023 | 62,000.00 |
| Dec 31, 2022 | 206,000.00 |
| Sep 30, 2022 | 335,000.00 |
| Jun 30, 2022 | 144,000.00 |
| Mar 31, 2022 | 572,000.00 |
| Dec 31, 2021 | 2.73 Mn |